FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208957> ?p ?o ?g. }

• W4387208957 endingPage "S94" @default.
• W4387208957 startingPage "S94" @default.
• W4387208957 abstract "Patients with localized prostate cancer (PCA) treated with RT alone have excellent outcomes, making quality of life and minimization of toxicities of great concern. The risk of developing toxicity may evolve with time from treatment which is of interest to patients seen in follow up. The primary objective of this study is to determine the conditional risk of grade 2+ GI or GU toxicity for patients treated with RT. A secondary objective is to determine risk factors associated with the development of late toxicities.We performed a post-hoc analysis of RTOG 0126, which enrolled patients with intermediate risk PCa who were randomized to receive standard dose RT of 70.2 Gy in 39 fractions vs dose escalated dose RT (DE-RT) of 79.2 Gy in 44 fractions. Cumulative incidence was used to calculate risk of grade 2+ GU and grade 2+ GI toxicity at initial time points, as well as for patients who survived 2 years and 5 years without respective grade 2+ toxicity. Risk factors of age, race, urinary incontinence, baseline urinary frequency, acute GU toxicity, treatment arm, RT method (3DCRT vs IMRT), and OAR contouring protocol violation were analyzed using univariate and multivariate Cox proportional hazards modeling for late GU toxicity. Risk factors of age, race, RT method, acute GI toxicity, DE-RT, RT method, and OAR contouring protocol violation were analyzed for late GI toxicity.One thousand four hundred ninety-nine patients with a median follow up of 8.4 years (range 0.02-13 years) were included for analysis. The conditional cumulative 5-year risk of late grade 2+ GI toxicity at enrollment, 2-, and 5-years of grade 2+GI toxicity free survivorship was 14.7%, 6.2%, and 1.8% respectively. The cumulative 5-year risk of late grade 2+ GU toxicity at enrollment, 2-, and 5-years of late grade 2+ GU toxicity free survivorship was 7.9%, 4.7%, and 2.7% respectively. Initially DE-RT (HR 1.401, 95% CI 1.099-1.787; p = 0.0066), acute GI toxicity (HR 1.962, 95% CI 1.271-2.616; P<0.0001), and black race (HR 0.630, 95% CI 0.4-0.993; p<0.0463) were predictive of late GI toxicity. After two years of 2+ GI toxicity free survivorship, only acute GI toxicity (HR 2.015, 95% CI 1.238-3.279, p<0.0048) remained predictive of late GI toxicity on MVA. DE-RT (HR 1.616, 95% CI 1.187-2.2, p<0.0023), IMRT (HR 0.559, 95% CI 0.389-0.804, p = 0.0017), and urinary frequency at baseline (HR 1.377, 95% CI 1-1.895 p<0.0498) were predictive of late GU toxicity at enrollment.This data suggests that as patients proceed further from completion of EBRT, the conditional risk of late toxicity decreases. The majority of grade 2+ GI and GU toxicities occur in the first two years of treatment and patients who have not had a grade 2+ GU or GI toxicity within the first five years are likely to remain toxicity free. Factors such as presence of baseline urinary dysfunction, presence of acute toxicities, DE-RT, and radiation modality predict for late toxicity. These findings are of relevance for clinicians and patients in the post treatment setting." @default.
• W4387208957 created "2023-09-30" @default.
• W4387208957 creator A5004293130 @default.
• W4387208957 creator A5011761198 @default.
• W4387208957 creator A5024860393 @default.
• W4387208957 creator A5029090221 @default.
• W4387208957 creator A5044756712 @default.
• W4387208957 creator A5050135240 @default.
• W4387208957 creator A5073788259 @default.
• W4387208957 creator A5079362394 @default.
• W4387208957 creator A5083468059 @default.
• W4387208957 date "2023-10-01" @default.
• W4387208957 modified "2023-10-17" @default.
• W4387208957 title "Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126" @default.
• W4387208957 doi "https://doi.org/10.1016/j.ijrobp.2023.06.425" @default.
• W4387208957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784609" @default.
• W4387208957 hasPublicationYear "2023" @default.
• W4387208957 type Work @default.
• W4387208957 citedByCount "0" @default.
• W4387208957 crossrefType "journal-article" @default.
• W4387208957 hasAuthorship W4387208957A5004293130 @default.
• W4387208957 hasAuthorship W4387208957A5011761198 @default.
• W4387208957 hasAuthorship W4387208957A5024860393 @default.
• W4387208957 hasAuthorship W4387208957A5029090221 @default.
• W4387208957 hasAuthorship W4387208957A5044756712 @default.
• W4387208957 hasAuthorship W4387208957A5050135240 @default.
• W4387208957 hasAuthorship W4387208957A5073788259 @default.
• W4387208957 hasAuthorship W4387208957A5079362394 @default.
• W4387208957 hasAuthorship W4387208957A5083468059 @default.
• W4387208957 hasConcept C121608353 @default.
• W4387208957 hasConcept C126322002 @default.
• W4387208957 hasConcept C126894567 @default.
• W4387208957 hasConcept C141071460 @default.
• W4387208957 hasConcept C143998085 @default.
• W4387208957 hasConcept C144301174 @default.
• W4387208957 hasConcept C2780192828 @default.
• W4387208957 hasConcept C29730261 @default.
• W4387208957 hasConcept C38180746 @default.
• W4387208957 hasConcept C50382708 @default.
• W4387208957 hasConcept C509974204 @default.
• W4387208957 hasConcept C71924100 @default.
• W4387208957 hasConcept C72563966 @default.
• W4387208957 hasConcept C77411442 @default.
• W4387208957 hasConcept C88879693 @default.
• W4387208957 hasConceptScore W4387208957C121608353 @default.
• W4387208957 hasConceptScore W4387208957C126322002 @default.
• W4387208957 hasConceptScore W4387208957C126894567 @default.
• W4387208957 hasConceptScore W4387208957C141071460 @default.
• W4387208957 hasConceptScore W4387208957C143998085 @default.
• W4387208957 hasConceptScore W4387208957C144301174 @default.
• W4387208957 hasConceptScore W4387208957C2780192828 @default.
• W4387208957 hasConceptScore W4387208957C29730261 @default.
• W4387208957 hasConceptScore W4387208957C38180746 @default.
• W4387208957 hasConceptScore W4387208957C50382708 @default.
• W4387208957 hasConceptScore W4387208957C509974204 @default.
• W4387208957 hasConceptScore W4387208957C71924100 @default.
• W4387208957 hasConceptScore W4387208957C72563966 @default.
• W4387208957 hasConceptScore W4387208957C77411442 @default.
• W4387208957 hasConceptScore W4387208957C88879693 @default.
• W4387208957 hasIssue "2" @default.
• W4387208957 hasLocation W43872089571 @default.
• W4387208957 hasLocation W43872089572 @default.
• W4387208957 hasOpenAccess W4387208957 @default.
• W4387208957 hasPrimaryLocation W43872089571 @default.
• W4387208957 hasRelatedWork W2013727445 @default.
• W4387208957 hasRelatedWork W2111740844 @default.
• W4387208957 hasRelatedWork W2354584592 @default.
• W4387208957 hasRelatedWork W2361700749 @default.
• W4387208957 hasRelatedWork W2374376758 @default.
• W4387208957 hasRelatedWork W2388791444 @default.
• W4387208957 hasRelatedWork W274490372 @default.
• W4387208957 hasRelatedWork W2784206856 @default.
• W4387208957 hasRelatedWork W2793295628 @default.
• W4387208957 hasRelatedWork W2948913314 @default.
• W4387208957 hasVolume "117" @default.
• W4387208957 isParatext "false" @default.
• W4387208957 isRetracted "false" @default.
• W4387208957 workType "article" @default.